腎臓病の世界市場レポート 2025年

腎臓病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で1,494億4,000万米ドルに成長します。予測期間の成長は、世界の感染症管理、精密医療アプローチ、糖尿病と肥満の流行、ヘルスケア政策の変化、認知度の向上、スクリーニングに起因すると考えられます。予測期間における主な動向としては、腎臓ケアのための遠隔医療、予防腎臓学の重視、在宅透析の増加、再生療法の開発、食生活の改善と栄養摂取などが挙げられます。

腎臓病の罹患率の増加が予想され、腎臓病市場の成長を牽引すると期待されます。腎臓疾患には、腎臓の構造や機能に影響を及ぼすさまざまな疾患が含まれます。腎臓疾患の治療薬は、症状を管理し、タンパク質の損失を減らし、腎臓障害の進行を遅らせ、最終的には合併症を予防する上で重要な役割を果たします。2023年6月、Kidney Research UKの報告によると、英国では推定719万人が慢性腎臓病に罹患しており、これは人口の10％以上に相当し、2033年には761万人に増加すると予測されています。したがって、腎臓疾患の発生率の増加は、腎臓病市場の成長を促進する重要な要因となっています。

高血圧と糖尿病の有病率の増加は、腎臓病市場の成長に大きく貢献すると予想されます。動脈壁に対する血液の力の上昇を特徴とする高血圧と、高血糖値をもたらす代謝異常である糖尿病は、腎臓疾患の主な原因となっています。高血圧や糖尿病によって腎臓の細い血管に持続的な損傷が生じると、腎臓がダメージを受け、血液から老廃物や余分な水分を効果的に濾過する能力に影響を及ぼす可能性があります。全米糖尿病統計報告書によると、米国では2023年に約3,840万人が糖尿病に罹患し、人口の11.6％を占めるとされています。したがって、高血圧と糖尿病の有病率の増加が、腎臓病市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腎臓病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腎臓病市場：成長率分析
• 世界の腎臓病市場の実績：規模と成長, 2019-2024
• 世界の腎臓病市場の予測：規模と成長, 2024-2029, 2034F
• 世界腎臓病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎臓病市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 透析
• 手術
• その他の治療法
• 世界の腎臓病市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性腎障害
• 慢性的な腎臓病
• 末期腎疾患
• その他の適応症
• 世界の腎臓病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の腎臓病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断検査室
• その他のエンドユーザー
• 世界の腎臓病市場、医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 降圧剤
• 赤血球造血刺激因子（ESA）
• リン酸結合剤
• ビタミンD類似体
• 免疫抑制剤
• 世界の腎臓病市場、透析の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液透析
• 腹膜透析
• 世界の腎臓病市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腎臓移植
• 腎摘出術
• 腎動脈バイパス
• 尿管手術
• 世界の腎臓病市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ライフスタイルと食生活の改善
• 腎代替療法
• 緩和ケア

第7章 地域別・国別分析

• 世界の腎臓病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎臓病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎臓病市場：競合情勢
• 腎臓病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi Aventis LLC
• Bristol-Myers Squibb Company
• AstraZeneca Pharmaceuticals LP
• Abbott Laboratories
• Fresenius SE & Co. KGaA
• GlaxoSmithKline Plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎臓病市場2029：新たな機会を提供する国
• 腎臓病市場2029：新たな機会を提供するセグメント
• 腎臓病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Kidney diseases encompass a range of conditions affecting the function and structure of the kidneys, vital organs responsible for filtering waste and excess fluids from the blood, regulating electrolyte balance, and producing hormones that control blood pressure and red blood cell production.

The main types of treatments for kidney disease include medication, dialysis, surgery, and others. Medication involves the use of drugs or pharmaceutical substances to treat, manage, or prevent various medical conditions associated with kidney diseases. These treatments are indicated for conditions such as acute kidney injury, chronic kidney disease, end-stage renal disease, and others, administered through oral and parenteral routes of administration. Various end-users, including hospitals and diagnostic laboratories, utilize these treatments.

The kidney disease research report is one of a series of new reports from The Business Research Company that provides kidney disease market statistics, including the kidney disease industry's global market size, regional shares, competitors with a kidney disease market share, detailed kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the kidney disease industry. This kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kidney disease market size has grown strongly in recent years. It will grow from $107.29 billion in 2024 to $114.74 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising chronic health conditions, aging population, genetic predisposition, medical research and education, environmental factors

The kidney disease market size is expected to see strong growth in the next few years. It will grow to $149.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to global infectious disease management, precision medicine approaches, diabetes and obesity epidemic, healthcare policy changes, increased awareness and screening. Major trends in the forecast period include telemedicine for kidney care, focus on preventive nephrology, rise in home-based dialysis, regenerative therapies development, dietary modifications and nutrition.

The anticipated increase in the incidence of kidney diseases is expected to drive the growth of the kidney disease market. Kidney diseases encompass a range of conditions affecting the structure and function of the kidneys. Medications for kidney disorders play a crucial role in managing symptoms, reducing protein loss, and slowing the progression of kidney damage, ultimately preventing complications. In June 2023, Kidney Research UK reported that an estimated 7.19 million people in the UK were affected by chronic kidney disease, representing over 10% of the population and projected to rise to 7.61 million people by 2033. Therefore, the heightened incidence of kidney diseases serves as a significant driver propelling the growth of the kidney disease market.

The increasing prevalence of high blood pressure and diabetes is expected to contribute significantly to the growth of the kidney disease market. High blood pressure, characterized by elevated blood force against arterial walls, and diabetes, a metabolic disorder leading to high blood glucose levels, are major contributors to kidney diseases. The sustained damage caused by high blood pressure and diabetes to the small blood vessels in the kidneys can result in kidney damage, impacting their ability to effectively filter waste and excess fluids from the blood. According to the National Diabetes Statistics Report, approximately 38.4 million people in the United States will have diabetes in 2023, constituting 11.6% of the population. Therefore, the increasing prevalence of high blood pressure and diabetes is a driving force behind the growth of the kidney disease market.

An emerging trend gaining traction in the kidney disease market is the integration of AI-driven tools. Companies in the kidney disease market are adopting new technologies, particularly AI solutions, to enhance patient outcomes and maintain their competitive edge. For instance, in November 2022, Carenostics, a US-based healthcare startup specializing in AI solutions, has introduced a product designed to analyze electronic health record (EHR) data for the early identification of chronic kidney disease (CKD). By seamlessly integrating AI-powered clinical decision support models into healthcare providers' EHR systems, Carenostics empowers clinicians to accurately identify high-risk patients with chronic diseases, facilitating proactive measures for improved patient outcomes.

Major companies in the kidney disease market are adopting a strategic partnership approach to enhance patient care, drive innovation, and expedite the commercialization of therapies. For instance, in June 2023, Southern California Kidney Consultants Inc., a US-based medical practices company, has partnered with Strive Health, a US-based healthcare company, to improve kidney disease treatment and care. The partnership involves 21 providers primarily based in Orange County, serving 5,000 patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, completed the acquisition of CinCor Pharma Inc. for $1.8 billion. This strategic move enables AstraZeneca to bolster its cardiorenal portfolio by incorporating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat, an aldosterone synthase inhibitor (ASI), is designed to lower blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company specializing in kidney disease medications and treatments.

Major companies operating in the kidney disease market include Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, Abbott Laboratories, Fresenius SE & Co. KGaA, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Kyowa Kirin Co. Ltd., Cipla Inc., Endo International plc., Lupin Limited, Kissei Pharmaceutical Co. Ltd.

North America was the largest region in the kidney disease market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney disease market consists of revenues earned by providing services such as hemodialysis, peritoneal dialysis, and kidney transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney disease also includes sales of drugs such as galafold, sibnayal, tarpeyo, and cystadrops. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Dialysis; Surgery; Other Treatments
• 2) By Indication: Acute Kidney Injury; Chronic Kidney Disease; End-Stage Renal Disease; Other Indication
• 3) By Route Of Administration: Oral; Parenteral
• 4) By End-User: Hospitals; Diagnostic Laboratories; Other End-Users
• Subsegments:
• 1) By Medication: Antihypertensives; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Vitamin D Analogs; Immunosuppressants
• 2) By Dialysis: Hemodialysis; Peritoneal Dialysis
• 3) By Surgery: Kidney Transplant; Nephrectomy; Renal Artery Bypass; Ureteral Surgery
• 4) By Other Treatments: Lifestyle And Dietary Modifications; Renal Replacement Therapy; Palliative Care
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Disease Market Characteristics

3. Kidney Disease Market Trends And Strategies

4. Kidney Disease Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Kidney Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kidney Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kidney Disease Market Growth Rate Analysis
• 5.4. Global Kidney Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kidney Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kidney Disease Total Addressable Market (TAM)

6. Kidney Disease Market Segmentation

• 6.1. Global Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Dialysis
• Surgery
• Other Treatments
• 6.2. Global Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Kidney Injury
• Chronic Kidney Disease
• End-Stage Renal Disease
• Other Indication
• 6.3. Global Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Kidney Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Laboratories
• Other End-Users
• 6.5. Global Kidney Disease Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihypertensives
• Erythropoiesis-Stimulating Agents (ESAs)
• Phosphate Binders
• Vitamin D Analogs
• Immunosuppressants
• 6.6. Global Kidney Disease Market, Sub-Segmentation Of Dialysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemodialysis
• Peritoneal Dialysis
• 6.7. Global Kidney Disease Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kidney Transplant
• Nephrectomy
• Renal Artery Bypass
• Ureteral Surgery
• 6.8. Global Kidney Disease Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lifestyle And Dietary Modifications
• Renal Replacement Therapy
• Palliative Care

7. Kidney Disease Market Regional And Country Analysis

• 7.1. Global Kidney Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kidney Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Disease Market

• 8.1. Asia-Pacific Kidney Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Disease Market

• 9.1. China Kidney Disease Market Overview
• 9.2. China Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Disease Market

• 10.1. India Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Disease Market

• 11.1. Japan Kidney Disease Market Overview
• 11.2. Japan Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Disease Market

• 12.1. Australia Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Disease Market

• 13.1. Indonesia Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Disease Market

• 14.1. South Korea Kidney Disease Market Overview
• 14.2. South Korea Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Disease Market

• 15.1. Western Europe Kidney Disease Market Overview
• 15.2. Western Europe Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Disease Market

• 16.1. UK Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Disease Market

• 17.1. Germany Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Disease Market

• 18.1. France Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Disease Market

• 19.1. Italy Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Disease Market

• 20.1. Spain Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Disease Market

• 21.1. Eastern Europe Kidney Disease Market Overview
• 21.2. Eastern Europe Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Disease Market

• 22.1. Russia Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Disease Market

• 23.1. North America Kidney Disease Market Overview
• 23.2. North America Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Disease Market

• 24.1. USA Kidney Disease Market Overview
• 24.2. USA Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Disease Market

• 25.1. Canada Kidney Disease Market Overview
• 25.2. Canada Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Disease Market

• 26.1. South America Kidney Disease Market Overview
• 26.2. South America Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Disease Market

• 27.1. Brazil Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Disease Market

• 28.1. Middle East Kidney Disease Market Overview
• 28.2. Middle East Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Disease Market

• 29.1. Africa Kidney Disease Market Overview
• 29.2. Africa Kidney Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kidney Disease Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kidney Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Disease Market Competitive Landscape And Company Profiles

• 30.1. Kidney Disease Market Competitive Landscape
• 30.2. Kidney Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Disease Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi Aventis LLC
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca Pharmaceuticals LP
• 31.6. Abbott Laboratories
• 31.7. Fresenius SE & Co. KGaA
• 31.8. GlaxoSmithKline Plc.
• 31.9. Takeda Pharmaceutical Company Limited
• 31.10. Eli Lilly and Co Ltd.
• 31.11. Gilead Sciences Inc.
• 31.12. Amgen Inc.
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Teva Pharmaceutical Industries Ltd.
• 31.15. Astellas Pharma Inc.

32. Global Kidney Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Disease Market

34. Recent Developments In The Kidney Disease Market

35. Kidney Disease Market High Potential Countries, Segments and Strategies

• 35.1 Kidney Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kidney Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kidney Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer